drugset / Trial / NCT05170503
Neoadjuvant Immunochemotherapy in Locally Advanced Esophagogastric Junction Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to access the safety and efficacy of neoadjuvant Immunotherapy (Sintilimab, PD-1 inhibitor) combined with chemotherapy (Tegafur+Oxaliplatin) for locally advanced esophagogastric junction adenocarcinoma.
Timeline
- Start
- 2021-12-29
- Primary completion
- 2026-01-01
- Completion
- 2029-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 130 mg/m2 | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Tegafur | Unknown | 40 mg/m2 | Oral |
| Subject | Tegafur | Unknown | 50 mg/m2 | Oral |
| Subject | Tegafur | Unknown | 60 mg/m2 | Oral |